The increasing use of GLP-1 analogues, such as semaglutide (Ozempic, Wegovy, and others), raises significant questions about their prescription and widespread use. Originally developed to treat type 2 diabetes, they are now increasingly used for weight loss, even in people without a strict clinical indication.
Their effectiveness in reducing appetite is supported by medical evidence, but the increase in prescriptions outside of established criteria creates risks: failure to address sustainable dietary changes, exposure to adverse effects, and potential shortages for patients with diabetes who rely on these drugs for metabolic control.
The accelerated medicalization of obesity can displace investment and attention to preventive measures such as nutrition education, access to healthy foods, physical activity, and public policies for less obesogenic environments.
Responsible prescribing involves evaluating each case, prioritizing clinical benefit, ensuring access to those most in need, and preventing demand from being driven primarily by trends or marketing. The challenge is to maintain the usefulness of this therapeutic tool without turning it into a fad solution with long-term negative consequences.
You can read the related news at: https://ledelab.co/noticias/ozempic-porciones-restaurantes-2025-08-07